VAMOX Co-Amoxiclav 250mg / 62.5mg per 5mL Powder for Suspension 120mL
RXDRUG-DRP-1104
Discreet Packaging
We recognize that purchasing medications can be a deeply personal matter. To respect your privacy, we ensure that all orders are packaged discreetly, with no indication of the contents on the packaging. This means that even our couriers remain unaware of the package contents.
Furthermore, we uphold strict confidentiality standards. We guarantee that your order information will never be disclosed to any third party. Your trust is paramount to us, and we are committed to safeguarding your privacy at every step of the process. Our dedication to discretion and confidentiality is part of our unwavering commitment to you, our valued customer.
FDA-registered Products
FDA-licensed Pharmacies
Features
Brand
VAMOX
Full Details
Dosage Strength
250 mg / 62.5 mg per 5 ml
Drug Ingredients
- Co-Amoxiclav
Drug Packaging
Powder for Suspension 120ml
Generic Name
Co-Amoxiclav
Dosage Form
Powder For Suspension
Registration Number
DRP-1104
Drug Classification
Prescription Drug (RX)
Description
Indications/Uses
For the treatment of infections due to susceptible organisms which include infections of the urinary tract, respiratory tract and skin. It is also used for otitis media and post-operative infections.
Susceptible organisms are β-lactamase producing strains of Haemophilus influenzae and Moraxella (Branhamella) catarrhalis which cause lower respiratory infections; β-lactamase producing strains of Haemophilus influenzae and Moraxella (Branhamella) catarrhalis causing otitis media and sinusitis; and β-lactamase producing strains of Staphyloccocus aureus, Escherichia coli, Klebsiella spp and Enterobacter spp which cause skin and skin structure infections.
Susceptible organisms are β-lactamase producing strains of Haemophilus influenzae and Moraxella (Branhamella) catarrhalis which cause lower respiratory infections; β-lactamase producing strains of Haemophilus influenzae and Moraxella (Branhamella) catarrhalis causing otitis media and sinusitis; and β-lactamase producing strains of Staphyloccocus aureus, Escherichia coli, Klebsiella spp and Enterobacter spp which cause skin and skin structure infections.
Dosage/Direction for Use
Children: Based on body weight 20-40 mg/Kg/day Or as prescribed by the physician.
Administration
May be taken with or without food: Preferably taken at the start of meals for better absorption & to reduce GI discomfort.
Contraindications
Contraindicated to patients with hypersensitivity to drug penicillin and with history of cholestatic jaundice or hepatic dysfunction associated with this drug.
Special Precautions
Co-amoxiclav possesses the characteristic low toxicity of the penicillin group of antibiotics. Periodic assessment of organ system functions, including renal, hepatic and hematopoietic function, is advisable during prolonged therapy. A high percentage of patients with mononucleosis who received ampicillin develop a skin rash. Thus, ampicillin class antibiotics are excreted in milk.
Therefore caution should be exercised when Co-amoxiclav is administered to a nursing woman.
Therefore caution should be exercised when Co-amoxiclav is administered to a nursing woman.
Adverse Reactions
Co-amoxiclav is generally well tolerated. The majority of side effects observed in clinical trials were of mild and transient nature and less than 3% of patients discontinued therapy because of drug-related side effects. The most frequently reported side effects were diarrhea/loose stools, nausea, skin rashes and urticaria, increased with the higher recommended dose. Other less frequently reported reactions include abdominal discomfort, flatulence, and headache.
Co-amoxiclav possesses the characteristic low toxicity of the penicillin group at antibiotics. Periodic assessment of organ system functions, including renal, hepatic and hematopoietic function, is advisable during prolonged therapy. A high percentage of patients with mononucleosis who received ampicillin develop a skin rash. Thus, ampicillin class antibiotics are excreted in milk; Therefore caution should be exercised when Co-amoxiclav is administered to a nursing woman.
Co-amoxiclav possesses the characteristic low toxicity of the penicillin group at antibiotics. Periodic assessment of organ system functions, including renal, hepatic and hematopoietic function, is advisable during prolonged therapy. A high percentage of patients with mononucleosis who received ampicillin develop a skin rash. Thus, ampicillin class antibiotics are excreted in milk; Therefore caution should be exercised when Co-amoxiclav is administered to a nursing woman.
Drug Interactions
Drug-drug: Chloramphenicol, macrolides, sulfonamides, tetracycline: decreased amoxicillin efficacy.
Hormonal contraceptives: decreased contraceptive efficacy.
Probenecid: decreased renal excretion and increased blood level of amoxicillin.
Hormonal contraceptives: decreased contraceptive efficacy.
Probenecid: decreased renal excretion and increased blood level of amoxicillin.
Caution For Usage
Direction for Reconstitution: For 400 mg/57 mg/5 mL. Powder for Suspension: To make up to 70 mL, shake bottle to loosen powder, then add 64 mL of distilled water and shake well to suspend powder. Keep reconstituted powder under refrigeration (2°C - 8°C). Discard after 10 days.
To make up to 10 mL, shake bottle to loosen powder, then add 9.2 mL of distilled water and shake well to suspend powder. Keep reconstituted powder under refrigeration (2°C - 8°C). Discard after 10 days.
For 250 mg/62.5 mg/5 mL Powder for Suspension: To make up to 60 mL, shake bottle to loosen powder, then add 53 mL of distilled water and shake well to suspend powder. Keep reconstituted powder under refrigeration (2°C - 8°C). Discard after 10 days.
To make up to 10 mL shake bottle to loosen powder, then add 8.5 ml of distilled water and shake well to suspend powder. Keep reconstituted powder under refrigeration (2°C - 8°C). Discard after 10 days.
Instructions and Special Precautions for Handling and Disposal: Do not freeze.
After reconstitution to form an oral suspension, this medicine should only be used up to 7 days from the dispensing data stated on the label.
Medicines should not be disposed of via wastewater or household waste. Ask the pharmacist how to dispose of medicines no longer use.
To make up to 10 mL, shake bottle to loosen powder, then add 9.2 mL of distilled water and shake well to suspend powder. Keep reconstituted powder under refrigeration (2°C - 8°C). Discard after 10 days.
For 250 mg/62.5 mg/5 mL Powder for Suspension: To make up to 60 mL, shake bottle to loosen powder, then add 53 mL of distilled water and shake well to suspend powder. Keep reconstituted powder under refrigeration (2°C - 8°C). Discard after 10 days.
To make up to 10 mL shake bottle to loosen powder, then add 8.5 ml of distilled water and shake well to suspend powder. Keep reconstituted powder under refrigeration (2°C - 8°C). Discard after 10 days.
Instructions and Special Precautions for Handling and Disposal: Do not freeze.
After reconstitution to form an oral suspension, this medicine should only be used up to 7 days from the dispensing data stated on the label.
Medicines should not be disposed of via wastewater or household waste. Ask the pharmacist how to dispose of medicines no longer use.
Storage
Store at temperatures not exceeding 25°C.
Action
Amoxicillin inhibits transpeptidase, preventing cross-linking of bacterial cell wall and leading to cell death. Addition of clavulanate (a beta-lactam) increases drug's resistance to beta-lactamase (an enzyme produced by bacteria that may inactivate amoxicillin).
MedsGo Class
Penicillins
Please sign in so that we can notify you about a reply